Risek is indicated for: Peptic ulcer: short and long term treatment of active benign gastric and active duodenal ulcers, including peptic ulcers associated with the use of non-steroidal anti-inflammatory drugs (NSAID) as well as with Helicobacter pylori infection. Gastro-oesophageal reflux disease: short and long term treatment of severe erosive oesophagitis associated with gastro-oesophagitis reflux disease, as well as management of acid-related dyspepsia (symptomatic gastro-oesophageal reflux disease). Zollinger-Ellison syndrome: management of pathologic gastric hypersecretion associated with Zollinger-Ellison syndrome (including cases resistant to other treatment). Acid aspiration: prophylaxis of acid aspiration during general anaesthesia (through gastric acid reduction).

DOSAGE OF RISEK 20MG 28CAP

Follow all directions given to you by your pharmacist or doctor carefully . They may differ from the information contained in this leaflet

Ask your pharmacist or doctor for help if you do not understand the instructions on the box .

The recommended dose is : –

Risek capsules should be taken immediately before meals, preferably in the morning and swallowed whole with liquid without crushing, breaking, or chewing. For those who have difficulty in swallowing, the capsules can be opened and intact granules within can be sprinkled on a tablespoon or mixed with fruit juice or yoghurt and swallowed immediately without chewing. Bengin gastric and duodenal ulcers: Risek 20 mg once daily for 8 weeks in gastric ulceration or 4 weeks in duodenal ulceration. Maintenance dose for prevention of relapse in patients with peptic ulcer: Risek 10 mg once daily, increased to Risek 20 mg once daily as needed, has been used. Severe or recurrent cases: Risek 40 mg once daily. Maintenance dose for recurrent ulcer: Risek 20 mg once daily. NSAID-associated duodenal or gastric ulcer and gastroduodenal erosions: Risek 20 – 40 mg once daily for 4 weeks, depending on whether the NSAID is continued or not. A further 4 weeks could follow, if needed. Prophylaxis in patients with a history of NSAID-associated duodenal or gastric ulcers, gastroduodenal lesions, or dyspeptic symptoms who require continued NSAID treatment: In a clinical study, Risek 10 mg once daily has been used successfully for the prevention of relapse in susceptible patients. Paeptic ulcer associated with Helicobacter pylori: H. pylori eradication phase: triple therapy regimens of Risek 20 mg, plus clarithromycin 500 mg, plus either amoxicillin 1000 mg or metronidazole 400 mg; all three medications are to be given twice daily for one week. Ulcer healing phase: Risek 20 – 40 mg once daily; treatment may need to be continued for 4 – 8 weeks to promote ulcer healing (particularly after ulcer haemorrhage or perforation). Gastro-oesophageal reflux disease: Risek 20 mg once daily for 4 weeks, followed by a further 4 – 8 weeks if not fully healed. Cases refractory to other treatment: Risek 40 mg once daily for 8 weeks. Long-term management of acid reflux disease in patients with healed reflux oesophagitis: Risek 10 mg daily increasing to Risek 20 mg once daily if symptoms return. Children over 2 years with severe ulcerating reflux oesophagitis: 0.7 – 1.4 mg/kg daily for 4 – 12 weeks; maximum daily dose should not exceed 40 mg. Acid-related dyspepsia (symptomatic gastro-oesophageal reflux disease): Risek 10 – 20 mg once daily for 2 – 4 weeks according to the response. Zollinger-Ellison syndrome: Initially Risek 60 mg once daily; usual range Risek 20 – 120 mg daily. Doses above 80 mg should be given in 2 divided doses. Prophylaxis of acid aspiration during general anaesthesia: Risek 40 mg on the preceding evening then Risek 40 mg 2 – 6 hours before surgery.

OVER-DOSAGE OF RISEK 20MG 28CAP

Single oral doses of up to 400 mg of omeprazole have not resulted in any severe symptoms. However, some clinical effects have been reported upon accidental ingestion of very high doses which may include blurred vision, confusion, diaphoresis, drowsiness, dryness of mouth, flushing, headache, nausea, and tachycardia. Treatment: Since there is no specific antidote for omeprazole, treatment is essentially symptomatic. Due to extensive protein binding, haemodialysis does not not remove an appreciable fraction of the total quantity of omeprazole or its metabolites.

CONTRA-INDICATION OF RISEK 20MG 28CAP

It is contraindicated in individuals with known hypersensitivity to omeprazole or any of its ingredients. Like other benzimidazole derivatives, omeprazole is better to be avoided during pregnancy and lactation until further research studies are available.

STORAGE OF RISEK 20MG 28CAP

Store at room temperature not exceeding 25 °C, in a dry place, protected from light.
PACK OF RISEK 20MG 28CAP
Packs of 28 capsules.
RISEK 20MG 28CAP MANUFACTURED BY
Julphar Gulf Pharmaceutical Industries, Ras Al Khaimah, U.A.E.

https://www.drugs.com/omeprazole.html

https://www.gardeniapharmacy.com/category/medicine-2/